Clinical Trials Logo

Clinical Trial Summary

A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.


Clinical Trial Description

This is a multi-center, open-label study of cinrebafusp alfa in combination with clinically established doses of ramucirumab and paclitaxel in patients with HER2-positive (IHC 3+ or IHC 2+ with HER2/neu gene amplification) gastric or GEJ adenocarcinoma (Arm 1) and in combination with tucatinib in patients with low levels of HER2 (IHC 1+ or IHC 2+ without HER2/neu amplification) (Arm 2). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05190445
Study type Interventional
Source Pieris Pharmaceuticals, Inc.
Contact Kayti Aviano
Phone +1-857-246-8287
Email [email protected]
Status Recruiting
Phase Phase 2
Start date November 1, 2021
Completion date February 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05070598 - Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer Phase 2
Recruiting NCT04082364 - Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3
Completed NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT04520295 - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT04450732 - Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Phase 1
Recruiting NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Recruiting NCT05091528 - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Phase 1/Phase 2
Recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Recruiting NCT04650451 - Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors Phase 1
Active, not recruiting NCT03650348 - PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Phase 1
Completed NCT04920747 - Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients